A Phase 2 interventional study of MAP0010 low dose and MAP0010 high dose in Asthma, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2014-01-09.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.
Among the 110 studies testing budesonide in Asthma, this one is the 85th largest by enrollment of the 108 interventional ones that give a count, is one of 12 that started in 2007, is one of 5 in phase 2, and was the 32nd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
University of British Columbia · Sites in Canada
Ages 19–49
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 51 · Phase 4 33
First in 1991; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 124 across the 108 interventional studies. Of the 94 that completed or were terminated, 35 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 110 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
11 studies in Asthma by AbbVie: none open now, 1 under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Asthma by AbbVie, this one is the 6th largest by enrollment, is one of 2 that started in 2007, is one of 6 in phase 2, and was the 3rd registered.
AbbVie’s Asthma studies by the year they started, since 2005.
1 of the studies testing budesonide in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 110 studies testing budesonide in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 11 in Asthma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the blood levels of two doses of MAP0010 (a corticosteroid) and two doses of an approved corticosteroid in adult asthma and safety with twice daily dosing over 7 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received Treatment 1 in period 1 followed by a 7 day washout period and then Treatment 2 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
Drug: MAP0010 low dose · Drug: Budesonide inhalation suspension 0.25mg
Subjects received Treatment 2 in period 1 followed by a 7 day washout period and then Treatment 1 period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
Drug: MAP0010 low dose · Drug: Budesonide inhalation suspension 0.25mg
Subjects received Treatment 3 in period 1 followed by a 7 day washout period and then Treatment 4 period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
Drug: MAP0010 high dose · Drug: Budesonide inhalation suspension 0.5mg
Subjects received Treatment 4 in period 1 followed by a 7 day washout period and then Treatment 3 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
Drug: MAP0010 high dose · Drug: Budesonide inhalation suspension 0.5mg
a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol
a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol
a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol
Also known as: Pulmicort Respules®
a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol
Also known as: Pulmicort Respules®
Cmax of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).
Time frame: Day 1 hour 12
Cmax of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).
Time frame: Day 8 hour 12
AUC(0-inf) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
The AUC(0-inf) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\*min/ml).
Time frame: Day 1 hour 12
AUC(0-inf) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
The AUC(0-inf) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\*min/ml).
Time frame: Day 8 hour 12
Half-life (t1/2) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.
Time frame: Day 1 hour 12
Half-life (t1/2) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.
Time frame: Day 8 hour 12
| Milestone | Treatment 1 Then Treatment 2 | Treatment 2 Then Treatment 1 | Treatment 3 Then Treatment 4 | Treatment 4 Then Treatment 3 |
|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 |
| Completed | 7 | 8 | 8 | 8 |
| Not completed | 1 | 0 | 0 | 0 |
| Milestone | Treatment 1 Then Treatment 2 | Treatment 2 Then Treatment 1 | Treatment 3 Then Treatment 4 | Treatment 4 Then Treatment 3 |
|---|---|---|---|---|
| Started | 7 | 8 | 8 | 8 |
| Completed | 7 | 8 | 7 | 8 |
| Not completed | 0 | 0 | 1 | 0 |
The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).
| pg/ml | MAP0010 High Dose | Pulmicort Respules® 0.50 mg | MAP0010 Low Dose | Pulmicort Respules® 0.25 mg |
|---|---|---|---|---|
| Cmax of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg | 250 ± 161 | 365 ± 203 | 168 ± 130 | 197 ± 102 |
The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).
| pg/ml | MAP0010 High Dose | Pulmicort Respules® 0.50 mg | MAP0010 Low Dose | Pulmicort Respules® 0.25 mg |
|---|---|---|---|---|
| Cmax of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg | 528 ± 257 | 530 ± 334 | 366 ± 262 | 315 ± 206 |
The AUC(0-inf) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\*min/ml).
| pg*min/ml | MAP0010 High Dose | Pulmicort Respules® 0.50 mg | MAP0010 Low Dose | Pulmicort Respules® 0.25 mg |
|---|---|---|---|---|
| AUC(0-inf) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg | 19400 ± 7280 | 55900 ± 19800 | 10300 ± 4620 | 26900 ± 7420 |
The AUC(0-inf) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\*min/ml).
| pg*min/ml | MAP0010 High Dose | Pulmicort Respules® 0.50 mg | MAP0010 Low Dose | Pulmicort Respules® 0.25 mg |
|---|---|---|---|---|
| AUC(0-inf) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg | 58700 ± 25700 | 90100 ± 38200 | 35500 ± 15000 | 45200 ± 19500 |
Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.
| min | MAP0010 High Dose | Pulmicort Respules® 0.50 mg | MAP0010 Low Dose | Pulmicort Respules® 0.25 mg |
|---|---|---|---|---|
| Half-life (t1/2) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg | 168 ± 95.7 | 207 ± 110 | 112 ± 49.0 | 179 ± 75.8 |
Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.
| min | MAP0010 High Dose | Pulmicort Respules® 0.50 mg | MAP0010 Low Dose | Pulmicort Respules® 0.25 mg |
|---|---|---|---|---|
| Half-life (t1/2) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg | 193 ± 67.2 | 192 ± 66.3 | 248 ± 192 | 230 ± 130 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment 1 Then Treatment 2 | — | 0/8 (0%) | 7/8 (87.5%) |
| Treatment 2, Then Treatment 1 | — | 0/8 (0%) | 2/8 (25%) |
| Treatment 3 Then Treatment 4 | — | 0/8 (0%) | 3/8 (37.5%) |
| Treatment 4 Then Treatment 3 | — | 0/8 (0%) | 3/8 (37.5%) |
| Event | Treatment 1 Then Treatment 2 | Treatment 2, Then Treatment 1 | Treatment 3 Then Treatment 4 | Treatment 4 Then Treatment 3 |
|---|---|---|---|---|
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/8 | 0/8 | 0/8 | 0/8 |
| NauseaGastrointestinal disorders | 1/8 | 0/8 | 0/8 | 0/8 |
| VomitingGastrointestinal disorders | 1/8 | 0/8 | 1/8 | 0/8 |
| MalaiseGeneral disorders | 1/8 | 0/8 | 0/8 | 0/8 |
| Skin infectionInfections and infestations | 0/8 | 1/8 | 0/8 | 0/8 |
| NasopharyngitisInfections and infestations | 0/8 | 1/8 | 0/8 | 0/8 |
| Viral infectionInfections and infestations | 0/8 | 0/8 | 1/8 | 0/8 |
| HeadacheNervous system disorders | 1/8 | 0/8 | 0/8 | 1/8 |
| SyncopeNervous system disorders | 0/8 | 0/8 | 0/8 | 1/8 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/8 | 0/8 | 1/8 | 1/8 |
| Age, Continuous(years) | Treatment 1 Then Treatment 2 | Treatment 2, Then Treatment 1 | Treatment 3 Then Treatment 4 | Treatment 4 Then Treatment 3 | Total |
|---|---|---|---|---|---|
| Mean | 27.4 ± 8.9 | 30.4 ± 7.2 | 30.0 ± 8.3 | 29.1 ± 6.9 | 29.2 ± 7.6 |
| Sex: Female, Male(Participants) | Treatment 1 Then Treatment 2 | Treatment 2, Then Treatment 1 | Treatment 3 Then Treatment 4 | Treatment 4 Then Treatment 3 | Total |
|---|---|---|---|---|---|
| Female | 3 | 6 | 3 | 7 | 19 |
| Male | 5 | 2 | 5 | 1 | 13 |
The record gives a start of Nov 2007, a primary completion of Jan 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 5 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide